toxylact

The first professional lActological database in the word

A07EA comprises locally acting intestinal corticosteroids used mainly for inflammatory bowel disease, which are generally considered low‑risk and compatible with breastfeeding when clinically indicated.atcddd.fhi+5

Classification and therapeutic group

ATC class A07EA “Corticosteroids acting locally” belongs to A07E intestinal anti‑inflammatory agents in the WHO ATC system.atcddd.fhi+3
It includes prednisolone (A07EA01), hydrocortisone (A07EA02), prednisone (A07EA03), betamethasone (A07EA04), tixocortol (A07EA05), budesonide (A07EA06) and beclometasone (A07EA07), formulated to act primarily in the intestinal lumen or mucosa.bmjopen.bmj+4

Formulations and indications

Medicinal products in A07EA encompass enemas and rectal foams for local treatment of ulcerative colitis and other colitides, as well as oral corticosteroids with poor systemic availability used solely for intestinal inflammatory diseases.atcddd.fhi+1
Certain oral and sublingual budesonide formulations targeting eosinophilic esophagitis or primary IgA nephropathy are also grouped here when their action is considered predominantly local, despite systemic routes of administration.atcddd.fhi+1

Mechanism of action

All A07EA medicines are glucocorticoids that bind to intracellular steroid receptors in intestinal mucosal cells, modulating gene transcription and reducing production of pro‑inflammatory cytokines, chemokines and adhesion molecules.academic.oup+2
Their local delivery and, in some cases, extensive first‑pass hepatic metabolism, are designed to maximize anti‑inflammatory action at the gut wall while limiting systemic corticosteroid exposure.pmc.ncbi.nlm.nih+2

Maternal pharmacokinetics

Rectal enemas and foams of hydrocortisone, prednisolone and similar agents achieve high local mucosal concentrations with relatively modest systemic absorption, influenced by mucosal integrity and disease activity.academic.oup+2
Oral and sublingual budesonide formulations in this group undergo substantial first‑pass metabolism, resulting in low systemic bioavailability and reduced overall maternal plasma levels compared with systemic corticosteroid regimens of similar nominal doses.academic.oup+2

Excretion into breast milk

Systemic and locally acting corticosteroids such as prednisone, prednisolone, budesonide and hydrocortisone are excreted into breast milk in small quantities, with peak milk levels typically occurring about 2 to 4 hours after dosing.academic.oup+4
Measured milk concentrations of prednisolone range from approximately 5 to 25% of maternal serum levels, and even at higher therapeutic doses infant exposure remains far below doses used therapeutically in neonates.academic.oup+1

Observed effects in breastfed infants

Clinical experience and observational studies indicate no significant adverse effects in infants breastfed by mothers receiving prednisone or prednisolone, including those treated for inflammatory bowel disease.academic.oup+3
No consistent signal of growth suppression, adrenal suppression, infection risk or developmental delay has been documented in association with maternal use of A07EA agents at standard doses, although data for some specific molecules (e.g. tixocortol, beclometasone in intestinal formulations) remain limited.academic.oup+3

Risk assessment for lactation

Expert reviews and clinical guidelines consider corticosteroids used for IBD, including locally acting intestinal and rectal preparations, to be low‑risk during breastfeeding, supporting continued lactation while these medicines are used.pubmed.ncbi.nlm.nih+3
Maintaining disease remission in the lactating parent is critical; undertreatment of ulcerative colitis or Crohn’s disease is more likely to harm both mother and child than the very low steroid dose the infant receives via breast milk.pubmed.ncbi.nlm.nih+3

Practical use and timing strategies

For mothers on A07EA agents, breastfeeding can usually continue without interruption; some clinicians optionally suggest breastfeeding immediately before dosing and allowing a 2–4‑hour interval before the next feed to avoid peak milk levels, although this is often considered unnecessary given the low absolute transfer.academic.oup+4
In high‑dose or prolonged systemic courses, infant monitoring for poor weight gain, lethargy, or signs of adrenal suppression may be prudent, but such complications remain rare at the doses typically used for intestinal inflammatory disease.academic.oup+2

Maternal toxicity considerations

Systemic corticosteroid adverse effects—such as hyperglycemia, hypertension, osteoporosis, mood changes and infection risk—remain relevant for the mother, even when agents are classified as “locally acting”, and should be balanced against the benefits of disease control.pmc.ncbi.nlm.nih+2
For rectal and low‑bioavailability preparations, these systemic risks are reduced compared with full‑dose systemic regimens, but not entirely absent, particularly in prolonged or repeated courses needed for chronic disease management.atcddd.fhi+2

Infant risk summary

Given the low breast‑milk transfer and lack of documented serious adverse effects, A07EA corticosteroids acting locally are generally compatible with breastfeeding when used at therapeutic doses for intestinal inflammatory conditions.academic.oup+4
The overall infant risk is considered very low; clinical vigilance should focus mainly on rare potential adrenal effects in the context of maternal high‑dose or multi‑drug immunosuppressive regimens, rather than on standard local therapies alone.academic.oup+2

Toxicological lactation category (Dimitar Kehayov)

Based on available pharmacokinetic and clinical data, intestinal and rectal locally acting corticosteroids in A07EA show minimal breast‑milk transfer, no expected toxicity in healthy term breastfed infants at usual maternal doses, and maternal use is limited primarily by the parent’s systemic steroid adverse‑effect profile rather than infant risk.academic.oup+7
Toxicological lactation category (Dimitar Kehayov): Category II – very low milk transfer; no expected infant toxicity at usual maternal doses; breastfeeding generally compatible, with clinical monitoring mainly for maternal steroid‑related adverse effects.academic.oup+5

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.